Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi:10.1056/NEJMoa0909530.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi:10.1016/S1470-2045(09)70364-X.
   PubMed Web of Science ®Google Scholar
• Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung ca ncer (NSCLC): an update. Discov Med. 2019;27(148):167–170.
   PubMed Web of Science ®Google Scholar
• Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9(1):34. doi:10.1186/s13045-016-0268-z.
   PubMedGoogle Scholar
• Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652. doi:10.1016/S1470-2045(16)30508-3.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674.
   PubMed Web of Science ®Google Scholar
• Manz SM, Losa M, Fritsch R, et al. Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therap Adv Gastroenterol. 2021;14:17562848211002018. doi:10.1177/17562848211002018.
   Web of Science ®Google Scholar
• Braun GS, Kirschner M, Rubben A, et al. [Side effects of novel cancer immunotherapies]. Nephrologe. 2020;15(3):191–204. doi:10.1007/s11560-020-00424-8.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013.
   PubMed Web of Science ®Google Scholar
• 崔久嵬, 段建春, 任胜祥, 苏春霞, 王志杰, 杨帆, et al. 三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识(2022年版). 中国肺癌杂志. 2022;25(09):627–641.
   Google Scholar
• Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–1238. doi:10.1016/j.annonc.2022.10.001.
   PubMed Web of Science ®Google Scholar
• Chen KL, Lin CC, Cho YT, et al. Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for Non-Small cell lung cancer. JAMA Dermatol. 2016;152(3):340–342. doi:10.1001/jamadermatol.2015.4448.
   PubMed Web of Science ®Google Scholar
• Patel AB, Pacha O. Skin reactions to immune checkpoint inhibitors. Adv Exp Med Biol. 2020;1244:235–246.
   PubMed Web of Science ®Google Scholar
• Annunziata MC, De Stefano A, Fabbrocini G, et al. Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig. 2019;39(9):825–834. doi:10.1007/s40261-019-00811-7.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Tan D, Yang JC-H, et al. Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in asia. J Thorac Oncol. 2023;18(4):436–446. doi:10.1016/j.jtho.2022.10.021.
   PubMed Web of Science ®Google Scholar
• Bhardwaj M, Chiu MN, Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73–90. doi:10.1080/15569527.2022.2034842.
   PubMed Web of Science ®Google Scholar
• Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128. doi:10.1016/j.currproblcancer.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Belum V, Benhuri B, Postow M, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Berlin: Springer; 2017.
   Google Scholar
• Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. doi:10.1016/j.jaad.2020.03.132.
   PubMed Web of Science ®Google Scholar
• Yalici-Armagan B, Ayanoglu BT, Demirdag HG. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. Cutan Ocul Toxicol. 2019;38(3):261–266. doi:10.1080/15569527.2019.1594874.
   PubMed Web of Science ®Google Scholar
• Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203–218. quiz 19–20. doi:10.1016/j.jaad.2014.07.032.
   PubMed Web of Science ®Google Scholar
• Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs. 2006;22(3):152–162. doi:10.1016/j.soncn.2006.04.005.
   PubMedGoogle Scholar
• Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. doi:10.1007/s00520-011-1197-6.
   PubMed Web of Science ®Google Scholar
• Carlisle JW, Ramalingam SS. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncol. 2019;15(8):805–816. doi:10.2217/fon-2018-0626.
   PubMed Web of Science ®Google Scholar
• Yi L, Fan J, Qian R, et al. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a meta-analysis. Int J Cancer. 2019;145(1):284–294. doi:10.1002/ijc.32097.
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR + NSCLC. J Thorac Oncol. 2021;16(5):740–763. doi:10.1016/j.jtho.2020.11.028.
   PubMed Web of Science ®Google Scholar
• Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022;40(27):3162–3171. doi:10.1200/JCO.21.02641.
   PubMed Web of Science ®Google Scholar
• Zhou C, Xie L, Liu W, et al. Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects. Ann Transl Med. 2021;9(10):867. doi:10.21037/atm-21-1606.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang Q, Zhang G, et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M + NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J Thorac Oncol. 2022;17(3):411–422. doi:10.1016/j.jtho.2021.10.024.
   PubMed Web of Science ®Google Scholar
• Group JHP. Hansoh Pharma’s Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer March 19, 2020 Available from: http://www.hspharm.com.
   Google Scholar
• Wu L, Zhong W, Li A, et al. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Ann Transl Med. 2021;9(11):950–950. doi:10.21037/atm-21-2823.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu H, Yang J. Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-Mutant Non-Small cell lung cancer case coupled with Osimertinib-Induced cardiotoxicity: case report and review. Front Endocrinol. 2022;13:833929. doi:10.3389/fendo.2022.833929.
   PubMed Web of Science ®Google Scholar
• Ding X, Ding J, Leng Z, et al. Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: a case series. Oncol Lett. 2022;24(5):400. doi:10.3892/ol.2022.13520.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. Non–small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13(5):515–524. doi:10.6004/jnccn.2015.0071.
   PubMed Web of Science ®Google Scholar
• Kris M, Johnson B, Kwiatkowski D, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s lung cancer mutation consortium (LCMC). J Clin Oncol. 2011;29(18_suppl):CRA7506–CRA7506. doi:10.1200/jco.2011.29.18_suppl.cra7506.
   Web of Science ®Google Scholar
• 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)小细胞肺癌诊疗指南-2021. 北京: 人民卫生出版社; 2021.
   Google Scholar